Intelligent Bio Solutions (INBS)
Portable fingerprint-sweat drug screening readers and consumables, with a distributed wearable patch.
Something off on this page? Send us feedback.
Sells the Intelligent Fingerprinting Drug Screening System, pairing portable readers with single-use fingerprint-sweat cartridges and accessories, plus a distributed wearable sweat patch. Revenue comes from product shipments and recurring cartridge orders, with the United Kingdom supplying most sales while broader U.S. commercialization awaits FDA clearance.
Centers on the Intelligent Fingerprinting Drug Screening System: a portable DSR-Plus Reader paired with single-use fingerprint-sweat cartridges for recent drug screening. The company sells readers, cartridges, and accessories, generating repeat purchases as customers replenish consumables; it also distributes the SmarTest Sweat Drug Testing Patch for longer-term monitoring.
Manufactures cartridges in Cambridge, sells directly in the United Kingdom, and reaches APAC, the Americas, and the rest of the world through agencies and distributors. United Kingdom sales provide most revenue, while U.S. use remains limited to Forensic Use Only settings pending FDA clearance. Cartridge production and an external reader-manufacturing partner underpin the active platform.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $4.0M · Total debt $1.8M · Total assets $11.9M · Shareholders' equity $5.5M
- Revenue
- $1.1M
- Operating income
- −$4.2M
- Net income
- −$3.9M
No dividends on record.
| Institutions12 holders · as of Sep 30, 2025 | 4.47% | 135.3K shares | |
| Insiders6 holders · as of Mar 20, 2026 | 2.93% | 88.6K shares | |
| Otherremainder | 92.60% | 2.80M shares |
3.03M company shares as of Sep 3, 2026 · institutions as of Sep 30, 2025 · holders as of their latest filing
Two share counts disagree (3.03M in the company's Sep 3, 2026 report, 645.8K elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Alyeska Investment Group, L.P.Institution | 2.22% | 673,492 | 13Fas of Sep 30, 2025 |
Adar1 Capital Management, LLCInstitution | 1.41% | 426,433 | 13Fas of Sep 30, 2025 |
Harry SimeonidisInsiderofficer: Chief Executive Officer | 1.14% | 34,540 | Form 4filed Mar 20, 2026 ↗ |
Spiro Kevin SakirisInsiderofficer: Chief Financial Officer | 1.12% | 33,981 | Form 4filed Mar 20, 2026 ↗ |
Vanguard Group IncInstitution | 0.32% | 97,686 | 13Fas of Sep 30, 2025 |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- Abbott
Portable oral-fluid screening with SoToxa readers and cartridges.
- Quest Diagnostics
Integrated workplace testing across oral fluid, urine, and laboratories.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Intelligent Bio Solutions | $2.41 | −2.75% | $1.6M | — | — | 0.4 | +44.6% |
| Abbott | $111.49 | +0.93% | $191.19B | 35.5 | 19.0 | 4.1 | +13.0% |
| Quest Diagnostics | $240.00 | −0.33% | $26.58B | 25.6 | 21.0 | 2.3 | +10.2% |
| Median | 30.5 | 20.0 | 3.2 | +11.6% |